Trial Profile
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2016
Price :
$35
*
At a glance
- Drugs Arsenic trioxide (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Jan 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 Jan 2008 New trial record.